Long-term outcomes of developmental exposure to fluoxetine: A review of the animal literature

Developmental Neuroscience

Volumn 35, Issue 6, 2013, Pages 437-449

  Kiryanova, Veronika ^a,c   McAllister, Brendan B ^a,c   Dyck, Richard H ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Animals; Developmental exposure; Fluoxetine; Mice; Rats

Indexed keywords

FLUOXETINE;

AGGRESSION; ANXIETY; CIRCADIAN RHYTHM; DEPRESSION; LEARNING; LOCOMOTION; MATERNAL STRESS; MEMORY; MOTOR COORDINATION; NEUROANATOMY; NONHUMAN; OUTCOME ASSESSMENT; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; REWARD; SENSORIMOTOR FUNCTION; SEXUAL BEHAVIOR; SOCIAL BEHAVIOR; TERATOGENICITY;

ANIMALS; ANXIETY; BRAIN; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TIME FACTORS;

EID: 84890530721     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000355709     Document Type: Review

References (80)

1. Noble RE: Depression in women. Metabolism 2005; 54: 49-52.
2. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R: Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198:e191-e195.
3. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898-906.
4. Cooper WO, Willy ME, Pont SJ, Ray WA: Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196:e541-e545.
5. Kim J, Riggs KW, Misri S, Kent N, Oberlander T, Grunau R, Fitzgerald C, Rurak D: Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006; 61: 155-163.
6. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W: Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32: 1253-1255.
7. Alwan S, Friedman JM: Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009; 23: 493-509.
8. Vitalis T, Parnavelas JG: The role of serotonin in early cortical development. Dev Neurosci 2003; 25: 245-256.
9. Nordquist N, Oreland L: Serotonin, genetic variability, behaviour, and psychiatric disorders-A review. Ups J Med Sci 2010; 115: 2-10.
10. Noorlander CW, Ververs FFT, Nikkels PGJ, van Echteld CJA, Visser GHA, Smidt MP: Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3:e2782.
11. Olivier JDA, Valles A, van Heesch F, Afrasiab-Middelman A, Roelofs JJPM, Jonkers M, Peeters EJ, Korte-Bouws GAH, Dederen JP, Kiliaan AJ, Martens G, Schubert D, Homberg J: Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology (Berl) 2011; 217: 419-432.
12. Malm H: Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome. Ther Drug Monit 2012; 34: 607-614.
13. Malm H, Artama M, Gissler M, Ritvanen A: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118: 111-120.
14. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A: Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66: 695-705.
15. Reis M, Kallen B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-1733.
16. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH: Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Br Med J 2009; 339:b3569.
17. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B: Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ (Clin Res Ed) 2012; 344:d8012.
18. Fornaro E, Li D, Pan J, Belik J: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007; 176: 1035-1040.
19. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J: A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994; 23: 194-205.
20. Müller JC, Boareto AC, Lourenco ELB, Zaia RM, Kienast MF, Spercoski KM, Morais RN, Martino-Andrade AJ, Dalsenter PR: In utero and lactational exposure to fluoxetine in Wistar rats: pregnancy outcomes and sexual development. Basic Clin Pharmacol Toxicol 2013; 113: 132-140.
21. Byrd RA, Markham JK: Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994; 22: 511-518.
22. Da Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ: Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res 1999; 32: 93-98.
23. Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S: Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007; 79: 1-11.
24. Cagiano R, Flace P, Bera I, Maries L, Cioca G, Sabatini R, Benagiano V, Auteri P, Marzullo A, Vermesan D, Stefanelli R, Ambrosi G: Neurofunctional effects in rats prenatally exposed to fluoxetine. Eur Rev Med Pharmacol Sci 2008; 12: 137-148.
25. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE: Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402-408.
26. Rayen I, Steinbusch H, Charlier TD, Pawluski JL: Developmental fluoxetine exposure and prenatal stress alter sexual differentiation of the brain and reproductive behavior in male rat offspring. Psychoneuroendocrinology 2013; 38: 1618-1629.
27. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L: Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 812-815.
28. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015.
29. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM: Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996-1000.
30. Wisner KL, Sit DKY, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT: Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166: 557-566.
31. Bauer S, Monk C, Ansorge M, Gyamfi C, Myers M: Impact of antenatal selective serotonin reuptake inhibitor exposure on pregnancy outcomes in mice. Am J Obstet Gynecol 2010; 203:e371-e374.
32. Cabrera TM, Battaglia G: Delayed decreases in brain 5-hydroxytryptamine2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther 1994; 269: 637-645.
33. Morrison JL, Chien C, Gruber N, Rurak D, Riggs W: Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Brain Res Dev Brain Res 2001; 131: 47-56.
34. Morrison JL, Riggs KW, Chien C, Gruber N, McMillen IC, Rurak DW: Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-Adrenal axes. Pediatr Res 2004; 56: 40-46.
35. Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira EG: Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007; 80: 49-56.
36. McAllister BB, Kiryanova V, Dyck RH: Behavioural outcomes of perinatal maternal fluoxetine treatment. Neuroscience 2012; 226: 356-366.
37. Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castrén E: Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009; 19: 97-108.
38. Rayen I, van den Hove DL, Prickaerts J, Steinbusch HW, Pawluski JL: Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One 2011; 6:e24003.
39. Forcelli PA, Heinrichs SC: Teratogenic effects of maternal antidepressant exposure on neural substrates of drug-seeking behavior in offspring. Addict Biol 2008; 13: 52-62.
40. Zheng J, Xu D-F, Li K, Wang H-T, Shen P-C, Lin M, Cao X-H, Wang R: Neonatal exposure to fluoxetine and fluvoxamine alters spine density in mouse hippocampal CA1 pyramidal neurons. Int J Clin Exp Pathol 2011; 4: 162-168.
41. Lee L-J, Lee LJ-H: Neonatal fluoxetine exposure alters motor performances of adolescent rats. Dev Neurobiol 2012; 72: 1122-1132.
42. Capello CF, Bourke CH, Ritchie JC, Stowe ZN, Newport DJ, Nemeroff A, Owens MJ: Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. J Pharmacol Exp Ther 2011; 339: 275-285.
43. Nagano M, Liu M, Inagaki H, Kawada T, Suzuki H: Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone. Neuropharmacology 2012; 63: 292-300.
44. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA: Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004; 306: 879-881.
45. Ansorge MS, Morelli E, Gingrich JA: Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008; 28: 199-207.
46. Smit-Rigter LA, Noorlander CW, von Oerthel L, Chameau P, Smidt MP, van Hooft JA: Prenatal fluoxetine exposure induces lifelong serotonin 5-HT 3 receptor-dependent cortical abnormalities and anxiety-like behaviour. Neuropharmacology 2012; 62: 865-870.
47. Francis-Oliveira J, Ponte B, Barbosa AP, Verissimo LF, Gomes MV, Pelosi GG, de Britto LR, Moreira EG: Fluoxetine exposure during pregnancy and lactation: effects on acute stress response and behavior in the noveltysuppressed feeding are age and gender-dependent in rats. Behav Brain Res 2013; 252C:195-203.
48. Andrews N, File SE: Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 1993; 235: 109-112.
49. Schmitt U, Hiemke C: Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. Pharmacol Biochem Behav 1998; 59: 807-811.
50. Lee LJ: Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 2009; 15: 212-223.
51. Vieira M, Hamada R, Gonzaga N, Bacchi A, Barbieri M, Moreira E, Mesquita S, Gerardin D: Could maternal exposure to the antidepressants fluoxetine and St John's wort induce long-term reproductive effects on male rats? Reprod Toxicol 2013; 35: 102-107.
52. Rodriguez-Porcel F, Green D, Khatri N, Harris SS, May WL, Lin RCS, Paul IA: Neonatal exposure of rats to antidepressants affects behavioral reactions to novelty and social interactions in a manner analogous to autistic spectrum disorders. Anat Rec 2011; 294: 1726-1735.
53. Knaepen L, Rayen I, Charlier TD, Fillet M, Houbart V, van Kleef M, Steinbusch HW, Patijn J, Tibboel D, Joosten EA, Pawluski JL: Developmental fluoxetine exposure normalizes the long-term effects of maternal stress on post-operative pain in Sprague-Dawley rat offspring. PLoS One 2013; 8:e57608.
54. Vartazarmian R, Malik S, Baker GB, Boksa P: Long-term effects of fluoxetine or vehicle administration during pregnancy on behavioral outcomes in guinea pig offspring. Psychopharmacology (Berl) 2005; 178: 328-338.
55. Kiryanova V, Smith VM, Dyck RH, Antle MC: The effects of perinatal fluoxetine treatment on the circadian system of the adult mouse. Psychopharmacology (Berl) 2013; 225: 743-751.
56. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V: Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011; 68: 1104-1112.
57. Gouvea TS, Morimoto HK, de Faria MJ, Moreira EG, Gerardin DC: Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice. Pharmacol Biochem Behav 2008; 90: 416-419.
58. Rayen I, Steinbusch H, Charlier TD, Pawluski JL: Developmental fluoxetine exposure facilitates sexual behavior in female offspring. Psychopharmacology (Berl) 2013, E-pub ahead of print.
59. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA: Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993; 262: 578-580.
60. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Müller U, Aguet M, Babinet C, Shih JC: Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995; 268: 1763-1766.
61. Singh Y, Jaiswal AK, Singh M, Bhattacharya SK: Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats. Indian J Exp Biol 1998; 36: 1023-1024.
62. Cabrera-Vera TM, Garcia F, Pinto W, Battaglia G: Effect of prenatal fluoxetine (Prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther 1997; 280: 138-145.
63. Silva CMd, Gonçalves L, Manhaes-de-Castro R, Nogueira MI: Postnatal fluoxetine treatment affects the development of serotonergic neurons in rats. Neurosci Lett 2010; 483: 179-183.
64. Cabrera-Vera TM, Battaglia G: Prenatal exposure to fluoxetine (Prozac) produces sitespecific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther 1998; 286: 1474-1481.
65. Pawluski JL, Rayen I, Niessen NA, Kristensen S, van Donkelaar EL, Balthazart J, Steinbusch HW, Charlier TD: Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 2012; 220: 131-141.
66. Favaro PDN, Costa LC, Moreira EG: Maternal fluoxetine treatment decreases behavioral response to dopaminergic drugs in female pups. Neurotoxicol Teratol 2008; 30: 487-494.
67. Ishiwata H, Shiga T, Okado N: Selective serotonin reuptake inhibitor treatment of early postnatal mice reverses their prenatal stressinduced brain dysfunction. Neuroscience 2005; 133: 893-901.
68. Ordian NE, Pivina SG, Fedotova IO, Akulova VK: Comparative efficacy of selective serotonin reuptake inhibitors in young prenatally stressed female rats (in Russian). Eksperimental'naia I Klinicheskaia Farmakologiia 2010; 73: 7-10.
69. Peters DA: Prenatal stress: effects on brain biogenic amine and plasma corticosterone levels. Pharmacol Biochem Behav 1982; 17: 721-725.
70. Pawluski JL, Charlier TD, Fillet M, Houbart V, Crispin HT, Steinbusch HW, van den Hove DL: Chronic fluoxetine treatment and maternal adversity differentially alter neurobehavioral outcomes in the rat dam. Behav Brain Res 2012; 228: 159-168.
71. Heikkinen T, Ekblad U, Palo P, Laine K: Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330-337.
72. Catterson ML, Preskorn SH: Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996; 78: 203-208.
73. Brown AP, Dinger N, Levine BS: Stress produced by gavage administration in the rat. Contemp Top Lab Anim Sci 2000; 39: 17-21.
74. Meijer MK, Spruijt BM, van Zutphen LFM, Baumans V: Effect of restraint and injection methods on heart rate and body temperature in mice. Lab Anim 2006; 40: 382-391.
75. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S: Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 2005; 144: 695-702.
76. Johns JM, Joyner PW, McMurray MS, Elliott DL, Hofler VE, Middleton CL, Knupp K, Greenhill KW, Lomas LM, Walker CH: The effects of dopaminergic/serotonergic reuptake inhibition on maternal behavior, maternal aggression, and oxytocin in the rat. Pharmacol Biochem Behav 2005; 81: 769-785.
77. Meaney MJ: Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci 2001; 24: 1161-1192.
78. Holson RR, Pearce B: Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol Teratol 1992; 14: 221-228.
79. Montero D, de Ceballos ML, Del Rio J: Downregulation of 3 H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sci 1990; 46: 1619-1626.
80. Romero G, Toscano E, Del Río J: Effect of prenatal exposure to antidepressants on 5-HTstimulated phosphoinositide hydrolysis and 5-HT 2 receptors in rat brain. Gen Pharmacol 1994; 25: 851-856.